Public Market Momentum Avalyn completed a high-profile IPO in April 2026, raising about $300 million and achieving a strong first-day surge, signaling robust investor appetite for inhaled respiratory therapies and potential for strategic partnerships to accelerate commercialization.

Inhaled ILD Pipeline Lead candidate AP01 (inhaled pirfenidone) in Phase 2b MIST and AP02 (inhaled nintedanib) with completed Phase 1 studies position Avalyn to offer differentiated, tolerability-friendly therapies for interstitial lung diseases, creating opportunities for licensing, co-development, and device collaboration with biotech and pharma.

Strategic Leadership Expansion Recent hires and board appointment signal readiness to scale operations, governability, and pursue major partnerships, licensing deals, or acquisitions to accelerate product development and commercialization.

Clinical Collaboration Footprint Active engagement with major conferences such as ATS and EULAR demonstrates a focus on engaging key opinion leaders and clinical trial networks, offering opportunities to secure collaboration agreements, investigator-sponsored studies, and early access programs.

Financial Position for BD With a revenue range of $25M-$50M and IPO-backed funding runway, Avalyn has a credible platform to enter partnerships, co-fund trials, or co-market inhaled therapies as they move from Phase 2 to potential commercialization.